Atherosclerosis in the Back Yard  by Herrmann, Joerg & Lerman, Amir
I
p
w
i
p
“
m
v
p
t
b
t
c
t
e
o
a
t
i
t
i
t
w
e
s
“
m
i
p
t
F
M
o
Journal of the American College of Cardiology Vol. 49, No. 21, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PFOCUS ISSUE: PLAQUE NEOVASCULARIZATION,
HEMORRHAGE, AND VULNERABILITY Commentary
Atherosclerosis in the Back Yard
Joerg Herrmann, MD, Amir Lerman, MD
Rochester, Minnesota
The phenomenon of neovascularization in atherosclerosis has been widely recognized through “the eyes of novel
imaging techniques” in recent years. Oxidative stress, inflammation, and hypoxia have been implied as the un-
derlying mechanisms. The pathophysiologic consequences and therapeutic implications of this neovasculariza-
tion process for atherosclerosis have, however, remained challenging and controversial. In the current focus is-
sue of the Journal, 4 articles and this commentary are devoted to this topic. (J Am Coll Cardiol 2007;49:
2102–4) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.042n
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et was not until the end of the 20th century that the
henomenon of neovascularization in atherosclerosis was
idely recognized, mainly supported by “the eyes of novel
maging techniques” (1,2). However the reports on this
henomenon form just the introduction to the tale of
angiogenesis in atherosclerosis.” The currently expanding,
ore challenging, and controversial chapters relate to the
ery process of angiogenesis, its causal relationship with the
rogression and complication of atherosclerosis, and its
herapeutic implications. From vision to therapy, from
ench to bedside, this experience may eventually resemble
he process of “angiogenesis and the struggle to defeat
ancer” (3).
In atherosclerosis, the formation of new vessels around
he arterial wall can be seen even before the development of
ndothelial dysfunction and plaque formation (4). More-
ver, vasa vasorum neovascularization evolves mainly in the
rea of intimal thickening, indicating “cross-talk” between
he intima and the adventitia (5). Indeed, this neovascular-
zation process creates a potential entry port for inflamma-
ory and proliferative factors, red blood cells (RBCs), and
nflammatory cells from the circulation to the adventitia. In
his process, the media and subintimal space become “sand-
iched” between 2 highly vascular layers and directly
xposed to an extensive endothelial surface area on either
ide. As the atherosclerotic plaque develops, neovessels
sprout” from the adventitial vasa vasorum through the
edia into the intima lesion (2). Only a small fraction of the
ntima vessels can be traced back to the main lumen. The
laque areas that are particularly rich in neovessels include
he shoulder region and the base (2,6). Eventually, plaque
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Manuscript received January 24, 2007; accepted February 19, 2007.eovascularization seems to characterize not only the vul-
erable plaque but also the vulnerable patient (7). Thus,
ngiogenesis is an “associate” of atherosclerosis through its
arious stages.
Given the early onset of vasa vasorum neovascularization
n atherogenesis, factors other than hypoxia, classically
hought to be the main stimulus for angiogenesis, have to be
onsidered. Increased oxidative stress in the arterial wall
ay stimulate vasa vasorum neovascularization (8). Inflam-
ation may be another important factor, and there may
ven be a mutual interaction between vascular inflammation
nd neovascularization (9). As the atherosclerotic lesion
ncreases in volume, hypoxia may become a more prominent
timulus for neovessel formation (10). At that point, further
rowth of the atherosclerotic plaques may actually depend
n angiogenesis, reminiscent of a cancerous lesion (1).
espite the identification of a number of mechanisms that
an contribute to the neovascularization process, our under-
tanding of the regulation of this process in atherosclerosis
till remains incomplete (11).
A number of studies indicate that the newly formed
essels are leaky and fragile and for this reason may lead to
he extravasation of RBCs and even true intraplaque hem-
rrhage (12). Given the rich cholesterol content of RBCs,
his may contribute to the lipid loading of the atheroscle-
otic plaque, its progression in volume, and vulnerability. As
n additional factor, release of free hemoglobin can stimu-
ate oxidative stress and inflammation in the atherosclerotic
laque (2). The newly formed vessels may contribute to these
nfavorable plaque dynamics further by serving as conduits for
nflammatory cells and soluble factors (1). Moreover, proteo-
ytic enzyme activity during the neovascularization process may
eaken plaque structures, contributing to plaque vulnerability,
specially in the shoulder regions (13). Thus, the microvascu-
ature of the plaque may contribute to the progression and
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herapeutic interest.
A focus series in the current issue of the Journal addresses
he triad of plaque neovascularization, hemorrhage, and
ulnerability. In the first 2 papers in the series, Tziakas et al.
14) report and Arbustini (15) comments on the observation
hat the total cholesterol content of erythrocyte membranes
as more than 2 times higher in patients presenting with
cute coronary syndrome than in patients with chronic
table angina. The authors suggest that RBC total choles-
erol content may serve as a novel marker for atherosclerotic
laque progression and complication. The diagnostic and
rognostic value of RBC total cholesterol for atherosclerotic
ardiovascular disease, however, awaits confirmation.
In their viewpoint paper, Kolodgie et al. (16) expand on
he contribution of RBC cholesterol to atherosclerotic
laque growth and vulnerability via fragile plaque neoves-
els. As a logical extension, they introduce the concept of
ntiangiogenic therapy and highlight the option of local
rug therapy, possibly supplied on the platform of coated
tents. Doyle and Caplice (17) further review the opportu-
ities and pitfalls of antiangiogenic therapy in the context of
therosclerosis. Both groups agree that a multitargeted
pproach will most likely be required and call for rigorous
xperimental evaluation of this new treatment paradigm
efore clinical trials are considered.
Indeed, there is limited experimental experience with
ntiangiogenic therapy in atherosclerosis, and the findings
ave to be interpreted within the framework of a complex
nterplay of factors in vivo. Nevertheless, the agents that
ave shown promise include the natural inhibitors endosta-
in, a 20-kDa fragment released from the collagen XVIII,
nd angiostatin, an internal proteolytic fragment of plas-
inogen, as well as synthetic inhibitors such as TNP-470,
n analogue of fumagillin, and vascular endothelial growth
actor (VEGF) receptor-1 antagonists (18). A therapeutic
lternative would be to “simply” target inflammation and
xidative stress, given their pathophysiologic momentum.
n fact, the most successful drugs for the treatment of
therosclerosis, which are associated with antiinflammatory
nd antioxidative activities, have also been shown to exert
ntiangiogenic effects. Among these drugs are aspirin,
MG-CoA reductase inhibitors, and antagonists of the
enin-angiotensin system (19–22). However, specific anti-
ngiogenic agents may be needed to supplement and antag-
nize the progression and complication of atherosclerosis
eyond the accomplishments of these drugs.
Another important aspect in the consideration of antian-
iogenic therapy for atherosclerosis is the systemic and focal
ature of this disease, leading to the concept of the
ulnerable patient rather than a single vulnerable plaque.
his raises the question of how we should identify patients
ho are to benefit from antiangiogenic therapy. For local
herapy, this question would have to be extended toward the
dentification of the vulnerable plaque. Imaging methods are
volving but are not yet validated to allow routine assess-ent of the neovascularization
rocess in the plaque. This
ould be required to assess treat-
ent effects, including causality
etween intervention and out-
ome. If the interventions were
ruly catheter-based, a number of
echnical concerns would have to be addressed. Catheter-
ased interventions such as stenting lead to a remarkable
eovascularization response themselves and harbor the risk
f procedure-induced end-organ injury (22–25). The cur-
ent generation of drug-eluting stents has some antiangio-
enic potency; in direct comparison, however, angiostatin
nhibits endothelial cell proliferation and neointima forma-
ion more strongly than paclitaxel (26). Considering their
otency and the likely need for prolonged therapy, systemic
multi-drug) antiangiogenic therapy is burdened with the
oncern of reducing collateral vessel formation and end-
rgan neovascularization, two processes of significance for
atients with diffuse atherosclerosis. In addition, at least
ome of these agents may affect not only endothelial cells of
ew vessels but also endothelial cells of existing vessels.
ypertension, proteinuria, and thrombosis, for example,
ave been reported with the use of VEGF antagonists and
ave been attributed to the interference with the physiologic
unctions of VEGF on the endothelium (18). Finally, the
ppropriate timing, drugs, and dosing of these therapies are
till unknown. Thus, both systemic and local antiangiogenic
herapies are associated with a number of uncertainties in
arget specification, efficacy, and side effects. However, these
pparent obstacles should be regarded only as challenges
hat can be overcome by future studies.
The next chapter in the book on “angiogenesis in ath-
rosclerosis” has yet to be written, but the miniseries in the
urrent issue of the Journal is already an important contri-
ution. Finally, it highlights our preoccupation with the
umen and the significance of the arterial back yard to the
rogression and complications of atherosclerosis.
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